MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer

Clinical Chemistry

Volumn 59, Issue 11, 2013, Pages 1595-1603

  Lichner, Zsuzsanna ^a,b   Fendler, Annika ^c   Saleh, Carol ^a   Nasser, Aurfan N ^b   Boles, Dina ^a,b   Al Haddad, Sahar ^c   Kupchak, Peter ^d   Dharsee, Moyez ^d   Nuin, Paulo S ^d   Evans, Kenneth R ^d   Jung, Klaus ^e   Stephan, Carsten ^e   Fleshner, Neil E ^f   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d MaRS Centre   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; MICRORNA; MICRORNA 125A; MICRORNA 125B; MICRORNA 127B; MICRORNA 135A; MICRORNA 141; MICRORNA 148A; MICRORNA 151 5P; MICRORNA 152; MICRORNA 174B; MICRORNA 193A; MICRORNA 196B; MICRORNA 19A; MICRORNA 19B; MICRORNA 20B; MICRORNA 26A; MICRORNA 26B; MICRORNA 29C; MICRORNA 331 3P; MICRORNA 347A; MICRORNA 365; MICRORNA 374B; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMICAL FAILURE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTENSIVE CARE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TREATMENT FAILURE; TUMOR GROWTH;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-3; RISK ASSESSMENT; TRANSCRIPTOME;

EID: 84887074767     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.205450     Document Type: Article

References (32)

1. Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 2007;51:605-13. (Pubitemid 46097288)
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
3. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998;160: 2096-101.
4. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Glea- son score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51. (Pubitemid 27208886)
5. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du CJ, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173:1938-42. (Pubitemid 40675216)
6. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 2008;14:4400 -7.
7. Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol 2009;78: 1083-94.
8. Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, et al. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol 2012;180:1675- 87.
9. Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 2011;57:954-68.
10. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: A stepping stone towards improved cancer management. Nat Rev Clin Oncol 2011;8:75- 84.
11. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
12. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27: 1788-93. (Pubitemid 351380263)
13. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67: 6130-5. (Pubitemid 47037493)
14. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166- 76.
15. Sun R, Fu X, Li Y, Xie Y, Mao Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 2009;10:93.
16. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010;127:394-403.
17. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008;68:1152- 64.
18. Xu G, Wu J, Zhou L, Chen B, Sun Z, Zhao F, Tao Z. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One 2010;5:e15519.
19. Zheng X, Chopp M, Lu Y, Buller B, Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 2012;329:146 -54.
20. Zhang J, Ying ZZ, Tang ZL, Long LQ, Li K. MicroRNA-148a promotes myogenic differentiation by targeting the ROCK1 gene. J Biol Chem 2012;287:21093-101.
21. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009;284:24696 -704.
22. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156: 1064-8. (Pubitemid 26269830)
23. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011; 17:7574-83.
24. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinasedependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-27. (Pubitemid 39469987)
25. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 2007;67:6544-8. (Pubitemid 47105497)
26. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413- 48. (Pubitemid 351822188)
27. Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, et al. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene 2013;32: 4139-47.
28. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, et al. miRNA-708 control of CD44(-) prostate cancer-initiating cells. Cancer Res 2012; 72:3618 -30.
29. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013;109: 641-50.
30. Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT, et al. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene [Epub ahead of print 2013 Jul 15].
31. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
32. Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, Penington DJ, Riese DJ II. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 2003;192: 67-74. (Pubitemid 36287662)